Background
It is estimated that about 13 % of US working-age adults are currently uninsured [
1]. The Affordable Care Act has the potential to continue to reduce the number of uninsured individuals in the US [
2]. Health insurance is an important first step to health care access for these individuals. Uninsured adults receive less appropriate care and have worse outcomes compared to those with insurance [
3‐
5]. More than 10 million adults in the US have albuminuria with preserved estimated glomerular filtration rate. Albuminuria is a well-established risk factor for chronic kidney disease (CKD) progression, cardiovascular events, and death [
6‐
12]. Although lack of health insurance is known to be an important predictor of adverse outcomes among individuals with various medical conditions [
3‐
5], its impact on mortality in adults with albuminuria has not been thoroughly evaluated. Prior work has shown that individuals who belong to racial and ethnic minority groups and those of lower socioeconomic status (SES) have a greater risk of albuminuria, and have greater health consequence associated with albuminuria [
12‐
14]. The objective of this study is to evaluate the association of insurance status with all-cause and cardiovascular mortality among working-age adults with albuminuria in the Third National Health and Nutrition Examination Survey, 1988–1994 (NHANES III).
Results
In our study population (Table
1), the mean age at the time of the interview was 42 years, 63 % of participants were women, 67 % were non-Hispanic White, 16 % were non-Hispanic Black, 6 % were Mexican American and 11 % were of other racial/ethnic background. In addition, approximately 37 % had income less than 200 % FPL, 74 % had less than high school education and 64 % were married. In this sample of NHANES participants, 40 % of participants reported excellent or very good health, 36 % had hypertension, 24 % had diabetes, 44 % had hypercholesterolemia, and 6 % reported cardiovascular disease. The mean eGFR was 102 mL/min/1.73 m
2 and median UACR was 71 mg/g. Overall, 4.7 % of the participants had eGFR < 60 ml/min/1.73 m
2 and 11.5 % had UACR ≥ 300 mg/g.
Table 1
Characteristics of individuals with albuminuria (age < 65) overall and stratified by insurance status
N= | 903 | 197 | 203 | 503 | |
Age | 41.90 (0.69) | 38.26 (1.77) | 44.88 (1.93) | 41.90 (0.81) | 0.04 |
Age group |
< 45 | 57.39 | 67.65 | 44.82 | 58.56 | 0.045 |
45–65 | 43.54 | 35.87 | 55.54 | 42.05 | 0.079 |
Gender |
Male | 37.38 | 31.02 | 36.53 | 39.00 | 0.541 |
Female | 62.62 | 68.98 | 63.47 | 61.00 |
Race |
Non-Hispanic Whites | 66.67 | 51.03 | 49.86 | 74.55 | <.001 |
Non-Hispanic Black | 16.29 | 15.37 | 29.56 | 12.97 | <.001 |
Mexican American | 5.90 | 16.36 | 5.09 | 3.82 | <.001 |
Other | 11.14 | 17.24 | 15.49 | 8.65 | 0.108 |
Income |
< 100 FPL | 17.54 | 41.76 | 40.55 | 7.27 | <.0001 |
101–200 FPL | 19.92 | 28.27 | 30.27 | 15.85 | 0.0014 |
> 200 FBL | 62.54 | 29.97 | 29.18 | 76.88 | <.001 |
FPL (Median, IQR) | 193.8 (104.2,331.3) | 96.6 (58.1,156.4) | 95.6 (63.25,165.15) | 250.6 (154.8,379.9) | |
Education |
< High School | 73.79 | 90.17 | 87.93 | 66.45 | <.001 |
> = High School | 26.21 | 9.83 | 12.07 | 33.55 |
Marital Status | | | | | |
Married | 64.10 | 58.98 | 42.90 | 70.84 | <.001 |
Previously Married | 16.70 | 18.04 | 32.50 | 12.23 | <.001 |
Never Married | 19.19 | 22.98 | 24.61 | 16.93 | 0.200 |
Self-rated Health |
Excellent/Very Good | 40.45 | 28.74 | 25.65 | 46.93 | 0.004 |
Good | 37.42 | 36.83 | 33.16 | 38.68 | 0.595 |
Fair/Poor | 22.13 | 34.43 | 41.20 | 14.39 | <.001 |
Usual Source of Care (Yes) | 83.02 | 65.93 | 88.39 | 85.35 | <.001 |
Usual Care Provider (Yes) | 72.95 | 50.58 | 70.03 | 78.64 | <.001 |
Smoking (Yes) | 33.75 | 29.77 | 45.98 | 31.39 | 0.032 |
Hypertension (Yes) | 36.14 | 34.12 | 45.22 | 34.18 | 0.248 |
Systolic BP, mm Hg | 127.31 (0.96) | 127.43 (3.08) | 128.08 (3.03) | 127.09 (1.28) | 0.921 |
Diastolic BP, mm Hg | 77.80 (0.55) | 78.34 (1.44) | 78.19 (1.34) | 77.57 (0.74) | 0.670 |
BMI |
< 30 kg/m2 | 65.28 | 62.77 | 62.57 | 66.55 | 0.801 |
> =30 kg/m2 | 34.72 | 37.23 | 37.43 | 33.45 |
Diabetes (Yes) | 23.60 | 25.44 | 36.05 | 19.91 | 0.010 |
HbA1C | 6.02 (0.10) | 6.16 (0.18) | 6.21 (0.18) | 5.94 (0.14) | 0.240 |
History of CVD (Yes) | 5.53 | 5.23 | 12.39 | 3.79 | 0.010 |
ACE Use (Yes) | 13.19 | 20.88 | 18.72 | 10.62 | 0.097 |
Cholesterol (Yes) | 43.80 | 49.71 | 40.23 | 43.45 | 0.427 |
Statin Use (Yes) | 4.48 | 10.33 | 7.52 | 2.81 | 0.277 |
Mean eGFR | 101.61 (1.18) | 105.40 (3.20) | 97.87 (4.02) | 101.76 (1.48) | 0.250 |
eGFR < 60 (%) | 4.74 | 3.46 | 9.30 | 3.81 | 0.177 |
Albuminuria Median (IQR) | 70.92 (43.02,154.42) | 69.48 (40.47,123.40) | 98.28 (46.51,265.43) | 67.09 (42.46,143.50) | |
UACR |
30–299 | 88.52 | 90.99 | 83.47 | 89.32 | 0.288 |
> =300 | 11.48 | 9.01 | 16.53 | 10.68 |
The weighted prevalence of uninsured, public insurance and private insurance was 15, 18 and 67 %, respectively. Compared to individuals with private insurance, those with public insurance or no insurance were significantly more likely to belong to a racial/ethnic minority group, to have income <200 % FPL, and to have less than high school education (p < 0.05 for each comparison). Uninsured individuals were younger and less likely to report a usual source of care than their insured counterparts (private or public), all p < 0.05. Individuals with public insurance differed from their privately (and non-insured counterparts) in that they were more likely to be non-Hispanic Black, to report fair/poor health, to be previously married, and to have hypertension, diabetes or cardiovascular disease, all p < 0.05. There were no significant differences in mean eGFR, UACR, statin use, or ACE-i use by insurance status.
All-cause and cardiovascular mortality by insurance status and access to care for individuals with albuminuria
The age-adjusted all-cause mortality rate for individuals with albuminuria was 13.5/1000 person-year (Table
2). Crude rates of all-cause mortality were higher in in the uninsured and individuals with public insurance than in those with private insurance (17.8 and 24.1 vs 10.4, respectively). A similar pattern was observed with cardiovascular mortality rates.
Table 2
Mortality rate by insurance status for individuals with albuminuria
Overall | 13.53 | 5.16 |
Insurance status (ref: Private) | 10.39 | 4.14 |
Uninsured | 17.76 | 7.02 |
Public | 24.06 | 8.06 |
In fully adjusted models, compared to individuals with private insurance, being uninsured was associated with increased risk for all-cause mortality (HR 2.97, 95 % CI 1.29–6.85). Compared to individuals with private insurance, having public insurance was also associated with increased mortality (HR 3.65, 95 % CI 1.74–7.67) (Table
3). There was a suggestion of effect modification by eGFR; however, due to low proportion of individuals with eGFR < 60 stratified analyses could not be done. We found no interaction between insurance status and race/ethnicity, gender, or age.
Table 3
Risk for all-cause mortality by insurance status and access to care for individuals with albuminuria
N= | 913 | | 913 | |
Unadjusted HR |
No Insurance V Private (REF) | 1.30(0.77,2.21) | 0.316 | 1.30(0.50,3.40) | 0.581 |
Public V Private | 2.75(1.61,4.68) | <.001 | 2.30(1.12,4.72) | 0.024 |
HR, Model 1a
|
No Insurance V Private (REF) | 1.80(0.74,4.34) | 0.189 | 1.96(0.66,5.77) | 0.219 |
Public V Private | 1.70(0.87,3.34) | 0.118 | 1.73(0.63,4.76) | 0.285 |
HR, Model 2b
|
No Insurance V Private (REF) | 1.86(0.71,4.87) | 0.199 | 1.88(0.46,7.58) | 0.370 |
Public V Private | 1.66(0.81,3.43) | 0.165 | 1.48(0.47,4.65) | 0.492 |
HR, Model 3c
|
No Insurance V Private (REF) | 1.90(0.83,4.34) | 0.125 | 1.95(0.56,6.85) | 0.288 |
Public V Private | 1.87(1.01,3.46) | 0.046 | 1.57(0.52,4.73) | 0.417 |
HR, Model 4d
|
No Insurance V Private (REF) | 2.97(1.29,6.85) | 0.012 | 2.15(0.44,10.46) | 0.337 |
Public V Private | 3.65(1.74,7.67) | <.001 | 3.21(0.77,13.43) | 0.107 |
The age-adjusted cardiovascular mortality rate for individuals with albuminuria was 5.16/1000 person-year (Table
2). In fully adjusted models, the cardiovascular mortality risk was similar between individuals with private insurance vs uninsured vs public insurance. We found no significant interaction between insurance status and age, gender, race, or eGFR on cardiovascular mortality.
Discussion
In this nationally representative sample of individuals with albuminuria and preserved eGFR, we found that both uninsurance and public insurance were associated with a significantly higher risk for mortality compared to private insurance. Uninsured individuals with albuminuria had nearly a three-fold higher risk for all-cause mortality than their privately insured counterparts after controlling for socioeconomic and clinical characteristic. Similar to our findings, the Kidney Early Evaluation Program (KEEP), a community-based health screening program, found an increased risk for death in uninsured participants with CKD stages 1–2 as compared to those with private insurance [
20]. Our study provides corroborative evidence in a sample representative of the US population.
We found that in a working age, US population with albuminuria, 15 % were uninsured, 18 % had public insurance, and 67 % had private insurance. Uninsurance was higher than a previous examination of uninsured adults with CKD because we looked only at individuals younger than 65 whom comprise over 90 % of the uninsured with CKD [
21]. Our uninsurance rate was closer to Wilper et al. who also used NHANES to examine uninsurance in working age adults [
5,
22].
In the general population, the association of uninsurance with increased risk for mortality is well established [
5,
23,
24]. However, the relationship between insurance status and outcomes has not been as well studied in the CKD population. In a cross-sectional analysis of data from NHANES, uninsured individuals with CKD were less likely to have controlled hypertension or to receive an angiotensin-converting enzyme inhibitor (ACEi) than those with insurance [
21,
25]. At the time of our study, rates of both ACEi and statin use were low in the general population [
26,
27]. Although we did not find a significant difference in rates of ACEi use across insurance categories, adding ACEi and statin to our final model increased both the magnitude and significance of the association between uninsurance and mortality. These findings suggest that ACE/statin are important mediators of the association or that they are potentially in the causal pathway.
Publicly insured individuals with albuminuria also had a significantly higher all-cause mortality rate than their privately insured counterparts. This finding was true both in the crude model and after adjusting for socioeconomic and clinical characteristics. For most working-age adults, eligibility for public insurance is dependent on income and poor health [
28]. In a national survey data study, Sorlie et al. also reported increased mortality in individuals with public insurance as compared to those with employer provided insurance [
29]. Sorlie also found that in certain groups, public insurance was associated with increased mortality compared to uninsurance [
29].
Our findings that health insurance is an important predictor of mortality in individuals with kidney disease, many of whom had early signs of kidney disease, has important implications in the current climate of healthcare reform. The number of uninsured in the US has decreased due both to the economic recovery and implementation of Affordable Care Act. The uninsurance rate for working age adults, 18–64 years old, was estimated to be 12.4 % in late 2014 [
1]. Due to targeted policies, poor working adults saw the largest gains in insurance coverage, particularly in Medicaid expansion states [
1]. However, the uninsured have gained coverage through a combination of expansion of employer-based coverage, health insurance exchanges, extended parental coverage, and Medicaid expansion [
30]. More individuals may potentially benefit given the current eligibility, and requirement, for nearly all working age adults to obtain insurance. In addition, the association of public insurance with increased mortality will likely be reduced as eligibility is based on income rather than health status.
We found a less convincing relationship between insurance status and cardiovascular mortality. The uninsured did not have a significantly different CV mortality than their privately insured counterparts. This finding seems surprising given the importance of medical care in managing cardiovascular risk factors and intervening on cardiovascular events. One possible explanation is that uninsured individuals with CKD and CV disease may remain uninsured for less time than their healthier counterparts. Due either to the number or severity of CV risk factors, they are more likely to meet criteria for public insurance. One final explanation is that since everyone regardless of insurance status is eligible for medical care during a cardiovascular emergency, the effect of insurance status on access to life-saving CV care is less important.
Our study had several limitations. Because of the design of NHANES, we only had access to a single UACR and eGFR determination, rather than the multiple measures. However, prior studies have used this method to ascertain CKD [
21,
26]. In addition, we were able to determine insurance status only at a single point in time. Patients may have had only a limited period of uninsurance or insured patients may have subsequently lost their insurance. Nonetheless, our classification of insurance status based on a single assessment was associated with significant differences in long-term outcomes.
Conclusions
In conclusion, in a nationally representative sample of individuals with albuminuria and preserved eGFR, both uninsurance and public insurance were associated with increased mortality compared to private insurance, even after controlling for sociodemographic, health status, and health care variables. Given the burdens of kidney disease both to the affected individuals, families, and the health care system, we must wait to see if efforts to provide comprehensive health care—by improving access to care and the quality of care received—will be able to help to reduce costs, morbidity and mortality for those with early evidence of CKD.
Availability of data and materials
Acknowledgements
Support: The authors acknowledge support from a Pilot and Feasibility Award P30 DK092949 (Saunders), K23 DK103111 (Saunders), K24 DK092290 (Lash), K23 DK094829 (Ricardo), P30 DK092949 (Chin), K24 DK071933 (Chin).
Competing interests
Financial and Other Disclosure: Drs. Saunders, Ricardo, Chen, Chin and Lash have no conflicts of interest to disclose.
Authors’ contributions
MS participated in the conception and design of the study, interpretation of the data and drafting of the work; AC participated in design of the work and revising it critically for important intellectual content; JC participated in the acquisition and analysis of the data; MC participated in the interpretation of the data and revising it critically for important intellectual content; JL participated in the conception and design of the work, interpretation of the results, and revising it for critically important intellectual content. All authors read and approved the final manuscript.